Hospira Recalling 21 Million Units of Three Injectables

Hospira is voluntarily recalling a total of over 21 million units of three injectable products through three separate recalls. The recall was initiated by Hospira on June 30 and affects product in the U.S., Puerto Rico, Guam, Canada and Singapore.

The 20.69 million single-dose vials of the nonsteroidal anti-inflammatory drug, ketorolac tromethamine injection, is being recalled because the calcium salt is crystalizing. The recall involves 64 lots, 10 of which — totaling more than 3.25 million vials — carry the Novaplus label, according to an FDA enforcement

report.